The discovery of this hormone paved the way for Ozempic, making the Gila monster an enormously profitable gift to modern ...

Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies, microbiology and biomonitoring products, test assays, analytical reagents, and ...

Pembrolizumab is under clinical development by Merck and currently in Phase I for Kaposi Sarcoma ... whose tumors express PD-L1 as determined by test with disease progression on or after ...

The microfluidic chip device is consisted of PDMS construction, capillary tubes, dispensing needles ... After staining with MTT solution (5 mg/mL, 20 μL/well, 4 h) (Sigma-Aldrich, Merck KGaA, ...

Sometimes, children have problems with their Eustachian tubes and experience excessive ear infections ... Strep throat must be diagnosed by a throat culture or rapid antigen test at your healthcare ...

2007) for ImageJ (FIJI open-source software, United States) using parameters of tubes and branches ... clone CY115) were obtained from Merck (United States) and Cell Applications (United States), ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

Merck reported Q4 sales of $15.62 billion, up 7% YoY, exceeding the $15.49 billion estimate. Goldman Sachs raises Merck's price target to $135, citing growth potential. Get real-time earnings ...

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...